Janssen's esketamine meets in Phase III to prevent treatment-resistant depression relapse

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said intranasal esketamine (formerly JNJ-54135419) plus an oral antidepressant met the primary endpoint of

Read the full 247 word article

User Sign In